Heartflow, Inc., a Mountain View, CA-based leader in AI technology for coronary artery disease (CAD), received additional investments of approximately $98m through the sale and issuance of convertible notes by its parent company, Heartflow Holding, Inc.
This included new investment by Fidelity Management & Research Company and additional investments from existing investors including Janus Henderson Investors, Bain Capital Life Sciences, Hayfin, US Venture Partners (USVP), HealthCor, Capricorn Investment Group and Martis Capital. Certain members of Heartflow management and the Board of Directors also participated in the financing.
Proceeds from the convertible notes financing will support research and development efforts to further support Heartflow’s continued advancement of the coronary computed tomography angiography (CCTA)+Heartflow pathway as the definitive standard for the non-invasive diagnosis and management of CAD.
Led by John Farquhar, president and CEO, Heartflow is advancing coronary care by transforming coronary artery disease into a screenable, diagnosable, and manageable condition. Heartflow One is a non-invasive, precision coronary care platform providing patient insights throughout the guideline-directed CCTA pathway. The AI-driven platform – including Roadmap™ Analysis, FFRCT Analysis and Plaque Analysis – is supported by the ACC/AHA Chest Pain Guideline and backed by more than 600 peer-reviewed publications. Heartflow has helped clinicians manage over 400,000 patients worldwide.
FinSMEs
27/03/2025